patritumab
daiichi sankyo
['patritumab']
#asco22 ian krop conclusions from the phase i/2 study of patritumab deruxtecan. of course this begs the question of where we go from here but clearly adcs are the bomb - huge advance in chemo delivery. need to understand differences in ab, toxins and linkers 